Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
EXEL Analyst Ratings
Moderate Buy
10 Buy
7 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
EXEL Stock 12 Month Forecast
Average Price Target
$37.81
▲(0.24% Upside)
| Highest Price Target$45.00 | Average Price Target$37.81 | Lowest Price Target$29.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
Reiterated
03/19/25
RBC Capital
Reiterated
03/13/25
Truist Financial
Reiterated
03/13/25
Wells Fargo
Downgraded
02/24/25
Barclays
Reiterated
02/18/25
H.C. Wainwright
Reiterated
02/13/25
Stifel Nicolaus
Reiterated
02/12/25
Morgan Stanley
Reiterated
02/12/25
Piper Sandler
Reiterated
02/12/25
JMP Securities
$41
Buy
8.70%
Upside
Reiterated
02/12/25
Positive Outlook for Exelixis Driven by Promising Developments in Zanzalintinib and Cabozantinib
TD Cowen
$34→$38
Buy
0.74%
Upside
Reiterated
02/11/25
Exelixis: Buy Rating Backed by Strong Financial Performance, Promising Drug Pipeline, and Positive Risk/Reward Profile1:22 AM EXELIXIS (NASDAQ: EXEL) Buy (1) ESG $38.00 (Prior $34.00) SOLID Q4 BEAT; EXPECTING EXEL TO STAY INDEPENDENT AS PIPELINE IS OVERLOOKED THE TD COWEN INSIGHT EXEL reported Q4 revenues of $567M (+5% q/q) vs our $544M/cons $565M est. Cabo posted $513M vs our $495M/cons $504M. FY25 guidance of $1.95-$2.05B (+8-14% y/y) does not incl NET (4/3/25 PDUFA). We anticipate solid cabo NET launch and model $2.07B. Zanza has multiple data including Ph3 CRC ('25) and Ph3 nccRCC PFS & Ph2 HNSCC (H2:25). We anticipate EXEL staying independent. Pipeline is overlooked. Solid Q4; Expecting Solid Cabo NET Launch (4/3/25 PDUFA) – Many Ph3 Zanza & Q4 revs driven by +11% y/y cabo growth. Q4 non-GAAP EPS $0.55 beat our $0.49 and cons $0.45 ests.
Leerink Partners
$32
Hold
-15.16%
Downside
Reiterated
02/11/25
Exelixis Hold Rating Maintained Amidst Stable Financials and Awaited Trial Data
UBS
$30→$34
Hold
-9.86%
Downside
Reiterated
01/28/25
Exelixis (EXEL) PT Raised to $34 at UBSUBS analyst Ashwani Verma raised the price target on Exelixis (NASDAQ: EXEL) to $34.00 (from $30.00) while maintaining a Neutral rating.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
Reiterated
03/19/25
RBC Capital
Reiterated
03/13/25
Truist Financial
Reiterated
03/13/25
Wells Fargo
Downgraded
02/24/25
Barclays
Reiterated
02/18/25
H.C. Wainwright
Reiterated
02/13/25
Stifel Nicolaus
Reiterated
02/12/25
Morgan Stanley
Reiterated
02/12/25
Piper Sandler
Reiterated
02/12/25
JMP Securities
$41
Buy
8.70%
Upside
Reiterated
02/12/25
Positive Outlook for Exelixis Driven by Promising Developments in Zanzalintinib and Cabozantinib
TD Cowen
$34→$38
Buy
0.74%
Upside
Reiterated
02/11/25
Exelixis: Buy Rating Backed by Strong Financial Performance, Promising Drug Pipeline, and Positive Risk/Reward Profile1:22 AM EXELIXIS (NASDAQ: EXEL) Buy (1) ESG $38.00 (Prior $34.00) SOLID Q4 BEAT; EXPECTING EXEL TO STAY INDEPENDENT AS PIPELINE IS OVERLOOKED THE TD COWEN INSIGHT EXEL reported Q4 revenues of $567M (+5% q/q) vs our $544M/cons $565M est. Cabo posted $513M vs our $495M/cons $504M. FY25 guidance of $1.95-$2.05B (+8-14% y/y) does not incl NET (4/3/25 PDUFA). We anticipate solid cabo NET launch and model $2.07B. Zanza has multiple data including Ph3 CRC ('25) and Ph3 nccRCC PFS & Ph2 HNSCC (H2:25). We anticipate EXEL staying independent. Pipeline is overlooked. Solid Q4; Expecting Solid Cabo NET Launch (4/3/25 PDUFA) – Many Ph3 Zanza & Q4 revs driven by +11% y/y cabo growth. Q4 non-GAAP EPS $0.55 beat our $0.49 and cons $0.45 ests.
Leerink Partners
$32
Hold
-15.16%
Downside
Reiterated
02/11/25
Exelixis Hold Rating Maintained Amidst Stable Financials and Awaited Trial Data
UBS
$30→$34
Hold
-9.86%
Downside
Reiterated
01/28/25
Exelixis (EXEL) PT Raised to $34 at UBSUBS analyst Ashwani Verma raised the price target on Exelixis (NASDAQ: EXEL) to $34.00 (from $30.00) while maintaining a Neutral rating.
Best Analysts Covering Exelixis
Which Analyst Should I Follow If I Want to Buy EXEL and Sell After:
1 Month
xxx
Success Rate
15/24 ratings generated profit
Average Return
+9.12%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +9.12% per trade.
3 Months
xxx
Success Rate
21/24 ratings generated profit
Average Return
+27.65%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 87.50% of your transactions generating a profit, with an average return of +27.65% per trade.
1 Year
Success Rate
22/25 ratings generated profit
Average Return
+25.48%
reiterated a buy rating 13 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 88.00% of your transactions generating a profit, with an average return of +25.48% per trade.
2 Years
xxx
Success Rate
25/25 ratings generated profit
Average Return
+52.09%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +52.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
EXEL Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
0
0
0
0
0
Buy
29
25
19
28
28
Hold
14
15
17
21
20
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
44
41
36
49
48
Each month's total comprises the sum of three months' worth of ratings.
EXEL Financial Forecast
EXEL Stock Forecast FAQ
What is EXEL’s average 12-month price target, according to analysts?
Based on analyst ratings, Exelixis’s 12-month average price target is $37.81.
What is EXEL’s upside potential, based on the analysts’ average price target?
Exelixis has 0.24% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is EXEL a Buy, Sell or Hold?
Exelixis has a consensus rating of Moderate Buy which is based on 10 buy ratings, 7 hold ratings and 0 sell ratings.
What is Exelixis’s price target?
The average price target for Exelixis is $37.81. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $45.00 ,the lowest forecast is $29.00. The average price target represents 0.24% Increase from the current price of $37.72.
The highest analyst price target is $45.00 ,the lowest forecast is $29.00. The average price target represents 0.24% Increase from the current price of $37.72.
What do analysts say about Exelixis?
Exelixis’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of EXEL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.